Lebrikizumab in the personalized management of asthma

• DOI: 10.2147/btt.s28666
• Publication Date: 2012-09-15T01:54:19Z
• Authors: Neil Thomson; Manish Patel; Smith
• Keywords: Asthma management

There is a need for improved therapies severe asthma. Lebrikizumab, humanized monoclonal antibody that binds to interleukin (IL)-13, under development the treatment of poorly controlled This article reviews potential role IL-13 in pathogenesis asthma, efficacy and safety lebrikizumab humans, progress patient selection therapy. T-helper (Th2) cell-derived cytokine implicated inflammatory responses including serum immunoglobulin-E synthesis, mucus hypersecretion, subepithelial fibrosis. Blocking pro-inflammatory effects with has improve asthma control. Published data on are relatively limited. The late asthmatic response after inhaled allergen challenge reduced by almost 50%, following lebrikizumab. In Phase II study performed 219 adults despite corticosteroids (MILLY trial), produced an improvement prebronchodilator forced expiratory volume 1 second 5.5% compared placebo at 12 weeks, but had no other end points. Adverse were similar placebo, except musculoskeletal side occurred slightly more often Stratifying patients into high Th2 phenotype using periostin, which upregulated lung epithelial cells IL-13, may identify individuals responsive blockade IL-13. MILLY trial, was associated greater function elevated periostin levels those low levels. Two large III randomized trials uncontrolled underway establish when administered over 52-week period. These studies will also help determine whether identifying allows personalized approach